Medication info
Sevikar 5/40 mg

Sevikar 5/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tablet
Manufacturer / importer
Daiichi Sankyo Korea Co., Ltd.
Appearance
Pale yellow, round, film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2)/carton
Approval status
Active

MFDS item code 201004569 · Approved 2010.07.19 · Insurance code 680900050

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment : This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume : For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment : Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2. Patients who must not receive this medicine under Precautions for Use.) ∘Elderly patients : Treatment is generally started at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Importer
Daiichi Sankyo Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

Amlodipine or olmesartan medoxomil is used in patients with essential hypertension when blood pressure is not sufficiently controlled by monotherapy. These medications lower blood pressure, reducing the burden on the heart and blood vessels, and help effectively control blood pressure, thus reducing the risk of complications. Proper blood pressure management is crucial for maintaining health and contributing to the prevention of cardiovascular diseases.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment : This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume : For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment : Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2. Patients who must not receive this medicine under Precautions for Use.) ∘Elderly patients : Treatment is generally started at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medicine can cause serious damage to the fetus and newborn during the second and third trimesters of pregnancy, so treatment should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to individuals allergic to its active ingredients or similar components, pregnant or breastfeeding women, patients with severe liver dysfunction, severe aortic stenosis, biliary obstruction, patients on dialysis, those in a state of shock, and certain patients with diabetes or severely impaired kidney function. Patients with low blood pressure due to fluid or salt deficiency may experience hypotensive symptoms, so close monitoring is required initially, and appropriate action should be taken if hypotension occurs. As vasodilation can lead to hypotension, caution is advised for certain heart disease patients like those with aortic stenosis. Patients with heart failure should be carefully monitored, and those with impaired kidney function may experience kidney damage; close monitoring of their condition is required. Patients with decreased liver function should be cautious as the metabolism of this medicine may slow down. During treatment, side effects such as dizziness, headache, hypotension, edema, dyspepsia, skin rash may occur; therefore, any unusual symptoms should be discussed with healthcare professionals. This medicine may interact with other medications; you must inform your healthcare provider about any other medications you're taking, especially to avoid concurrent use with grapefruit juice. This medication should not be used during pregnancy, and those planning to become pregnant or already pregnant must consult a doctor. If breastfeeding, it's important to either discontinue nursing or stop taking the medication since it can transfer into breast milk and affect the infant. Safety and efficacy have not been established for children under the age of 18, so it is not recommended for that age group. Elderly patients may require dosage adjustments due to decreased kidney and liver function affecting the medication's effectiveness. In cases of overdose, severe hypotension, vasodilation, and tachycardia can occur, requiring immediate medical attention.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 80 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • double vision
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • pruritus
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain storage temperatures between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow, round, film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2)/carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.